Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
Halfdan Sorbye,Staffan Welin,Seppo W. Langer,Lene Weber Vestermark,Nanna Holt,Pia Österlund,Svein Dueland,Eva Hofsli,Marianne Grønlie Guren,Katarina Ohrling,Elke Birkemeyer,Espen Thiis-Evensen,Matteo Biagini,Henning Grønbæk,L. M. Soveri,Ingrid Holst Olsen,Birgitte Federspiel,J Assmus,Eva Tiensuu Janson,Ulrich Knigge +19 more
Reads0
Chats0
TLDR
Advanced GI-NEC patients should be considered for chemotherapy treatment without delay, and poor performance status, colorectal primary and elevated platelets and LDH levels were prognostic factors for survival.About:
This article is published in Annals of Oncology.The article was published on 2013-01-01 and is currently open access. It has received 770 citations till now.read more
Citations
More filters
Journal ArticleDOI
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
Marianne Pavel,Dermot O'Toole,Frederico Costa,Jaume Capdevila,David J. Gross,Reza Kianmanesh,Eric P. Krenning,Ulrich Knigge,Ramon Salazar,Ulrich-Frank Pape,Kjell Öberg +10 more
TL;DR: The goal of this paper is to update a more extensive review and guidelines paper published in 2012 with any pertinent update pertaining to the diagnosis and staging of individual prima prima cancer patients.
Journal ArticleDOI
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.
Guido Rindi,David S. Klimstra,Behnoush Abedi-Ardekani,Sylvia L. Asa,Frederik T. Bosman,Elisabeth Brambilla,Klaus J. Busam,Ronald R. de Krijger,Manfred Dietel,Adel K. El-Naggar,Lynnette Fernandez-Cuesta,Günter Klöppel,W. Glenn McCluggage,Holger Moch,Hiroko Ohgaki,Emad A. Rakha,Nicholas S. Reed,Brian Rous,Hironobu Sasano,Aldo Scarpa,Jean-Yves Scoazec,William D. Travis,Giovanni Tallini,Jacqueline Trouillas,J. Han van Krieken,Ian A. Cree +25 more
TL;DR: This work believes this conceptual approach can form the basis for the next generation of NEN classifications and will allow more consistent taxonomy to understand how neoplasms from different organ systems inter-relate clinically and genetically.
Journal ArticleDOI
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
Rocio Garcia-Carbonero,Halfdan Sorbye,Eric Baudin,Eric Raymond,Bertram Wiedenmann,Bruno Niederle,Eva Sedlackova,Christos Toumpanakis,Martin Anlauf,Jarosław B. Ćwikła,Martyn Caplin,Dermot O'Toole,Aurel Perren +12 more
TL;DR: a Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid , Spain; b Department of oncology, Haukeland University Hospital, Bergen , Norway; c Institut Gustave Roussy, Villejuif, and d Oncologie Médicale, Hôpitaux Universitaires Paris Nord Val de Seine, Paris , France.
Journal ArticleDOI
The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Olca Basturk,Zhaohai Yang,Laura H. Tang,Ralph H. Hruban,N. Volkan Adsay,Chad M. McCall,Alyssa M. Krasinskas,Kee-Taek Jang,Wendy L. Frankel,Serdar Balci,Carlie S. Sigel,David S. Klimstra +11 more
TL;DR: It is demonstrated that well differentiated PanNETs that are G3 by Ki67 are significantly less aggressive than bona fide poorly differentiated NECs, suggesting that the current World Health Organization G3 category is heterogenous, contains 2 distinct neoplasms, and can be further separated into well differentiatedPanNET with an elevated proliferation rate and well differentiated NEC.
Journal ArticleDOI
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander,Wouter A. van der Zwan,Jaap J.M. Teunissen,Boen L. R. Kam,Richard A Feelders,Wouter W. de Herder,Casper H.J. van Eijck,Gaston J H Franssen,Eric P. Krenning,Dik J. Kwekkeboom +9 more
TL;DR: PRRT with 177Lu-DOTATATE is safe with few side-effects and shows good response rates with PFS of 29 months and OS of 63 months and is a favorable therapeutic option in patients with metastatic bronchial and gastroenteropancreatic NETs that express somatostatin receptors.
References
More filters
Book
WHO Classification of Tumours of the Digestive System
TL;DR: WHO Classification of Tumours of the Digestive System - Libros de Medicina - Gastroenterologia oncologica - 128,25
Journal ArticleDOI
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
Al B. Benson,Thomas A. Abrams,Edgar Ben-Josef,P. Mark Bloomston,Jean F. Botha,Bryan M. Clary,Anne M. Covey,Steven A. Curley,Michael I. D'Angelica,Rene Davila,William D. Ensminger,John F. Gibbs,Daniel Laheru,Mokenge P. Malafa,Jorge Marrero,Steven G. Meranze,Sean J. Mulvihill,James O. Park,James A. Posey,Jasgit Sachdev,Riad Salem,Elin R. Sigurdson,Constantinos T. Sofocleous,Jean-Nicolas Vauthey,Alan P. Venook,Laura W. Goff,Yun Yen,Andrew X. Zhu +27 more
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
Andreas du Bois,Hans-Joachim Lück,Werner Meier,Hans-Peter Adams,Volker Möbus,SD Costa,Thomas Bauknecht,Barbara Richter,M. Warm,W. Schröder,S. Olbricht,Ulrike Nitz,Christian Jackisch,Günther Emons,Uwe Wagner,Walther Kuhn,Jacobus Pfisterer +16 more
TL;DR: The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
Journal ArticleDOI
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
TL;DR: The anaplastic neuroendocrine tumor is strongly responsive to therapy with combined etoposide and cisplatin and should be evaluated for this possibility with appropriate immune staining or electron microscopy.
Related Papers (5)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more